动物生技药品市场规模、份额、成长分析（按类型、收入、目标疾病、来源和地区）- 产业预测，2025 年至 2032 年

预计 2023 年全球兽用生技药品市场价值将达到 264.4 亿美元，到 2032 年将成长至 386.5 亿美元，预测期内（2025-2032 年）的复合年增长率为 4.31%。

随着人们对动物健康的重视程度不断提高以及饲主对宠物健康意识的不断增强，兽用生技药品市场正在经历显着增长。宠物拥有量的增加和畜牧业产量的上升进一步推动了该行业的扩张。通用感染疾病的增加凸显了预防措施的必要性，并加强了对兽用生技药品的投资。重组疫苗、DNA疫苗和单株抗体等下一代生技药品以及先进的生物技术平台等技术创新正在改变这一格局。此外，改进的低温运输物流和向偏远地区的广泛推广对于提高疫苗的可及性和有效性至关重要。总体而言，强有力的政府措施和合作研发努力正在为家牛、家禽、伴侣动物和水产养殖等各个领域创造充足的成长机会。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二次资料和一次资料方法
• 市场规模预测
• 市场假设与约束

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态与展望

• 市场概览
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2024年）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 定价分析
• 技术分析
• 案例研究
• 顾客购买行为分析

动物生技药品市场规模（按类型和复合年增长率）（2025-2032）

• 市场概览
• 疫苗
• 抗生素
• 驱虫药
• 生长促进剂

动物生技药品市场规模（按类型和复合年增长率）（2025-2032）

• 市场概览
• 家畜
• 伴侣动物

动物生技药品市场规模（按目标疾病和复合年增长率） (2025-2032)

• 市场概览
• 细菌感染疾病
• 病毒感染
• 寄生虫感染疾病
• 代谢紊乱

动物生技药品市场规模（依来源及复合年增长率）（2025-2032）

• 市场概览
• 细胞培养
• 灭活病原体
• 重组技术

动物生技药品市场规模（按地区）及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2024年）
• 主要企业简介
  • 公司详情
  • 产品系列分析
  • 按部门分類的公司份额分析
  • 收益同比对比（2022-2024 年）

主要企业简介

• Hipra
• Zoetis
• Boehringer Ingelheim
• Tsinghua Tongda
• Bayer Animal Health
• Intervet
• Elanco Animal Health
• Ceva Animal Health
• Vetoquinol
• Beijing SVA Vaccines Serums
• Virbac
• Harbin Veterinary Research Institute
• Shenzhen Kangtai Biological Products
• Chongqing Zhifei Biological Products
• Merck Animal Health

结论和建议

Global Veterinary Biologics Market size was valued at USD 26.44 billion in 2023 and is poised to grow from USD 27.58 billion in 2024 to USD 38.65 billion by 2032, growing at a CAGR of 4.31% in the forecast period (2025-2032).

The veterinary biologics market is experiencing notable growth driven by heightened emphasis on animal health and the rising awareness among pet owners regarding their pets' wellbeing. Increasing pet ownership and livestock production further fuel this sector's expansion. The rise in zoonotic diseases underscores the need for preventive measures, enhancing investment in veterinary biologics. Innovations such as recombinant vaccines, next-generation biologics like DNA vaccines and monoclonal antibodies, and advanced biotechnological platforms are transforming the landscape. Additionally, improved cold chain logistics and extensive outreach to remote areas are crucial for enhancing vaccine access and efficacy. Overall, robust government initiatives and collaborative R&D efforts present ample opportunities for growth across various segments, including cattle, poultry, companion animals, and aquaculture.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Veterinary Biologics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Veterinary Biologics Market Segments Analysis

The veterinary biologics market is segmented into type, species, target disease, source, and region. By type, the market is classified into vaccines, antibiotics, Antiparasitic, and growth promoters. Depending on the species, it is bifurcated into livestock and companion animals. According to target disease, the market is divided into bacterial infections, viral infections, parasitic infections, and metabolic disorders. As per the supported source, it is categorised into cell culture, inactivated pathogens, and recombinant technologies. Regionally, it is analyzed across North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.

Driver of the Global Veterinary Biologics Market

One of the key market drivers for the Global Veterinary Biologics Market is the increasing prevalence of zoonotic diseases that can be transmitted from animals to humans. As urbanization and human-animal interactions rise, the risk of such diseases escalates, prompting governments and healthcare organizations to prioritize animal health management. This, in turn, drives demand for vaccines and biologics that ensure the health and productivity of livestock and companion animals. Additionally, growing awareness among pet owners regarding animal health and the importance of preventive care further propels the market, as consumers seek effective solutions to protect their animals from infectious diseases.

Restraints in the Global Veterinary Biologics Market

One key market restraint impacting the global veterinary biologics market is the stringent regulatory environment governing the approval and commercialization of veterinary products. The complex and lengthy process for obtaining necessary certifications and licenses can delay market entry for new vaccines and therapeutics, hampering innovation and accessibility. Additionally, varying regulatory standards across countries may complicate international trade and distribution, limiting market potential for manufacturers. These challenges can create barriers for smaller companies and new entrants, fostering an environment where larger, established players dominate, ultimately stifling competition and reducing the overall growth potential of the veterinary biologics sector.

Market Trends of the Global Veterinary Biologics Market

The Global Veterinary Biologics market is experiencing a marked shift towards recombinant DNA and vector-based vaccines, reflecting an industry-wide trend favoring innovative and efficient solutions. This transition from traditional live and inactivated vaccines is driven by the advantages these novel technologies present, such as enhanced safety profiles, strain specificity, and rapid production capabilities, essential for addressing the challenges posed by emerging and mutating diseases. Investments from both established companies and startups in recombinant platforms are increasing, driven by advancements in cell culture and synthetic biology, ultimately aiming to meet the diverse health needs of both companion and large livestock animals.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Technology Analysis
• Case Studies
• Customer Buying Behavior Analysis

Global Veterinary Biologics Market Size by Type & CAGR (2025-2032)

• Market Overview
• Vaccines
• Antibiotics
• Antiparasitic
• Growth Promoters

Global Veterinary Biologics Market Size by Species & CAGR (2025-2032)

• Market Overview
• Livestock
• Companion Animals

Global Veterinary Biologics Market Size by Target Disease & CAGR (2025-2032)

• Market Overview
• Bacterial Infections
• Viral Infections
• Parasitic Infections
• Metabolic Disorders

Global Veterinary Biologics Market Size by Source & CAGR (2025-2032)

• Market Overview
• Cell Culture
• Inactivated Pathogens
• Recombinant Technologies

Global Veterinary Biologics Market Size & CAGR (2025-2032)

• North America (Type, Species, Target Disease, Source)
  • US
  • Canada
• Europe (Type, Species, Target Disease, Source)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Species, Target Disease, Source)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Species, Target Disease, Source)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Species, Target Disease, Source)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Hipra
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zoetis
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Tsinghua Tongda
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer Animal Health
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Intervet
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Elanco Animal Health
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ceva Animal Health
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vetoquinol
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Beijing SVA Vaccines Serums
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Virbac
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Harbin Veterinary Research Institute
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shenzhen Kangtai Biological Products
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Chongqing Zhifei Biological Products
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck Animal Health
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations